"I believe there is small group in treatment arm that the mri shows great improvement and they believe more delays may cause statistical significant advantage of vb111. Even if we will see success I believe due to what's happening it will be a modest success but I may be wrong"
So, basically the DSMC is probably no safety issues and no worse efficacy. Hence the trial is continuing. So, I guess the real hope is that there is a subset (maybe the ones with Fever induction) that are doing well. The co hopes this will be their path to approval..
Oren: "Right now avastin and vb111 I believe doing around the same"
They're doing the same but you don't think they've reached the 105 events. So what are you saying? That avastin is performing much better than it has historically?
Market Data 
Markets 
AI
